RECURSION PHARMACEUTICALS, INC. (RXRX) Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Recursion Pharmaceuticals, Inc. NASDAQ:RXRX Healthcare · Biotechnology
Mkt Cap $2.41B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
Recursion announced it will release Q3 2026 financial results after market close on Monday, November 2, 2026.
The company will host a webinar on Tuesday, November 3 at 8:00 am ET, live from the CGA-IGC Annual Meeting in Denver, featuring updated REC-4881 data in FAP, a KOL panel, and patient perspectives.
The release also reiterates that a regulatory update for REC-4881 is expected by the end of the year, framing the webinar as a precursor to that catalyst.
• 6d ago AI analysis › Press Release ⚠ 1
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Sanofi optioned the first development candidate from its multi-program collaboration with Recursion, triggering a $10 million milestone payment to Recursion.
This brings total upfront and milestone payments under the collaboration to $144 million, with Recursion eligible for more than $300 million in additional milestones plus low double-digit royalties on net sales if approved.
The potential first-in-class oral small molecule targets a dual target implicated in inflammatory disease and is expected to enter Phase 1 trials in 2027, with Sanofi funding and leading all further development — future payments flow through as profit to Recursion.
• 17d ago AI analysis › Press Release ⚠ 2
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
Recursion priced an underwritten offering of 61,540,000 Class A shares at $3.25 per share for approximately $200 million in gross proceeds.
The deal is led by Leerink, Goldman Sachs, Morgan Stanley, and Evercore, with participation from Janus Henderson, Invus, Longaeva, ARK Invest, and Driehaus.
For a clinical-stage AI drug discovery company, this extends the cash runway but meaningfully dilutes existing holders; closing is expected on or about October 16, 2026.
• 17d ago AI analysis › Press Release ● Major ⚠ 3
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
Recursion announced a $200 million oversubscribed follow-on offering with leading healthcare investors including Janus Henderson, ARK Invest, and Invus, alongside pipeline and partnership updates.
REC-4881 showed a 47% median total GI polyp burden reduction in FAP after 12 weeks with durability off treatment, and a registrational trial is targeted for 2H 2027 pending FDA discussions; REC-1245 posted 2 confirmed partial responses and a 91.7% disease control rate in Phase 1.
Sanofi optioned the first development candidate from their collaboration, triggering a $10 million milestone and bringing total payments to $144 million, with more than $300 million in additional milestones and low double-digit royalties available.
Including offering proceeds, cash of roughly $561 million as of September 30 extends the runway into 2029 — dilution is the trade-off for a substantially de-risked, funded pipeline.
• 17d ago AI analysis › Press Release ⚠ 2
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model
Recursion and Tempus AI have extended their multi-year data license agreement through November 2029, building on a collaboration first established in 2023 to apply foundation models to precision medicine.
Under the amended Master Agreement, discretionary license fees potentially totaling $84 million over the next two years were replaced with committed payments totaling $42 million over the next three years.
Recursion has also granted Tempus a non-exclusive, worldwide license to its proprietary RNA sequencing model TxFM under a separate agreement; financial terms of that license were not disclosed.
For Recursion, the extension secures the data partnership through 2029 and adds a monetization channel for its RNA foundation model, though the committed fee total is half the prior discretionary potential.
• 1mo ago AI analysis › Press Release ⚠ 6
The Market Just Told You Which Layer Of AI Biology It Is Paying For
This is a paid investor-awareness article promoting MindWalk Holdings (HYFT), not a disclosure from Certara; Market Equities Limited discloses it was compensated to increase visibility for MindWalk.
Certara's Q2 results are cited only as a foil: revenue of $93.3 million up 1%, adjusted EPS of $0.08 versus $0.10 consensus, and a roughly 16% share decline — data investors may already know from Certara's own August 4 filing.
The article's argument — that markets reward proprietary data layers over software or AI-native models — is promotional commentary from an interested publisher and should be treated as marketing, not analysis.
• 1mo ago AI analysis › Press Release ● Major ⚠ 2
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
Genentech exercised the first Validated Target Option under the neuroscience collaboration, advancing an unexplored target into a small molecule discovery program and validating Recursion's AI-native platform.
Pipeline updates include IND clearance for REC-7735 with a Phase 1/2 trial starting in 2H26, and a planned Presidential Plenary presentation of REC-4881 Phase 2 data in November.
Q2 revenue was $7.7 million, down from $19.2 million in the prior year, while the net loss narrowed to $131.0 million due to lower R&D and G&A expenses. Management lowered 2026 cash operating expense guidance to under $375 million, extending the cash runway into early 2028.
• 2mo ago AI analysis › Press Release
Recursion to Participate in Upcoming Investor Conferences
Recursion announced it will participate in two upcoming investor conferences to discuss its business and pipeline.
The company is scheduled to present at the Bank of America 2026 SMID Cap Executive Insights Event on August 11, 2026, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026.
Webcasts of the presentations will be made available on the Recursion Investor Relations website.
• 2mo ago AI analysis › Press Release
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Recursion granted inducement restricted stock unit awards covering an aggregate of 3,234,866 shares of Class A common stock to 24 new employees.
The awards were approved by the Compensation Committee on July 27, 2026, under the company’s 2024 Inducement Equity Incentive Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
Vesting begins one year from the commencement date, with 25% of shares vesting on the first quarterly date thereafter and 6.25% vesting quarterly until fully vested.
• 3mo ago AI analysis › Press Release
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
Recursion announced it will report its second quarter 2026 financial results on Wednesday, August 5, 2026, prior to the market open.
The company will host a conference call at 8:00 AM ET, which will be broadcast live via its X, LinkedIn, and YouTube accounts.
Recursion is a clinical-stage TechBio company utilizing its Recursion OS platform for drug discovery in areas such as oncology and rare disease.
• 3mo ago AI analysis › Press Release ⚠ 1
The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It
Equity Insider published a paid commentary on behalf of MindWalk Holdings Corp., arguing that the value in AI drug discovery lies in the underlying biological data layer rather than just the models.
The article profiles MindWalk's 'context layer' strategy and mentions Absci (ABSI) as a peer focused on generative design and a participant in a recent industry panel.
This third-party piece references MindWalk's financial results and platform launches to support its investment thesis regarding the sector.
• 4mo ago AI analysis › Press Release
Recursion to Participate in Upcoming Investor Conferences
Recursion announced it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026.
The release serves as a standard calendar notification for investors, with no new operational or financial disclosures.
Webcasts of the event will be available on the company's Investor Relations website.
• 4mo ago AI analysis › Press Release
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Recursion announced the grant of 2,991,840 inducement restricted stock units to 33 new employees.
The awards were approved by the Compensation Committee on May 26, 2026, under the company's 2024 Inducement Equity Incentive Plan.
These grants are permitted under Nasdaq Listing Rule 5635(c)(4) as inducements material to the commencement of employment.
• 5mo ago AI analysis › Press Release ● Major
Altitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake City
globenewswire.com • 5mo ago Press Release ● Major ⚠ 2
Recursion Reports First Quarter Financial Results and Provides Business Update
Recursion reported Q1 2026 revenue of $6.5 million, down from $14.7 million in the prior year due to the completion of specific Roche project phases.
Despite the revenue decline, the company significantly narrowed its net loss to $117.5 million from $202.5 million, driven by improved operational efficiency and reduced R&D expenses.
Clinical updates were positive, with REC-1245 showing a well-tolerated safety profile and REC-4881 demonstrating a 43% median reduction in polyp burden, prompting FDA engagement on a potential registrational pathway.
• 5mo ago AI analysis › Press Release ● Major
Recursion Announces Board Transition
globenewswire.com • 6mo ago Press Release ● Major
Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6
globenewswire.com • 6mo ago 
